American Century Companies Inc. Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

American Century Companies Inc. grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 23.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 330,514 shares of the company’s stock after buying an additional 63,550 shares during the period. American Century Companies Inc. owned 0.34% of Intellia Therapeutics worth $7,397,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in NTLA. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the period. GAMMA Investing LLC grew its stake in Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after buying an additional 2,459 shares in the last quarter. EntryPoint Capital LLC raised its holdings in Intellia Therapeutics by 61.1% during the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc raised its holdings in Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after acquiring an additional 1,980 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $21.46 on Tuesday. Intellia Therapeutics, Inc. has a fifty-two week low of $19.21 and a fifty-two week high of $34.87. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -4.00 and a beta of 1.77. The firm has a 50 day moving average price of $23.17 and a 200-day moving average price of $24.02.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. The firm’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same period last year, the firm posted ($1.40) EPS. As a group, equities research analysts predict that Intellia Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NTLA. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. cut their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Truist Financial reissued a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Stifel Nicolaus decreased their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.